-
Table of Contents
SARMs vs Tamoxifen: A Modern Comparison
Sports pharmacology is a constantly evolving field, with new substances and treatments being introduced to enhance athletic performance and aid in injury recovery. Two such substances that have gained popularity in recent years are Selective Androgen Receptor Modulators (SARMs) and Tamoxifen. Both have been touted for their ability to increase muscle mass and improve athletic performance, but how do they compare? In this article, we will delve into the pharmacology of SARMs and Tamoxifen, and discuss their potential benefits and risks for athletes.
What are SARMs?
SARMs are a class of compounds that selectively bind to androgen receptors in the body, mimicking the effects of testosterone. Unlike anabolic steroids, which also bind to androgen receptors but have a wide range of effects on the body, SARMs are designed to target specific tissues, such as muscle and bone, while minimizing side effects on other organs (Thevis et al. 2019). This makes them a potentially attractive option for athletes looking to increase muscle mass and strength without the negative effects of traditional steroids.
One of the most well-known SARMs is Ostarine, also known as MK-2866. It has been studied extensively for its potential use in treating muscle wasting diseases and has shown promising results in increasing lean body mass and improving physical function (Dalton et al. 2011). Other SARMs, such as Ligandrol and Andarine, have also shown similar effects in clinical trials (Kearbey et al. 2007; Gao et al. 2005).
What is Tamoxifen?
Tamoxifen, on the other hand, is a selective estrogen receptor modulator (SERM) that is commonly used in the treatment of breast cancer. It works by blocking the effects of estrogen in the body, which can help prevent the growth of estrogen-sensitive tumors (Jordan 2003). However, it has also been studied for its potential use in sports, particularly in the treatment of gynecomastia (enlarged breast tissue) in male athletes who use anabolic steroids (Kicman 2008).
Some athletes have also turned to Tamoxifen as a performance-enhancing drug, as it has been shown to increase testosterone levels and improve muscle strength and endurance (Velders et al. 2014). However, its use in sports is controversial and has been banned by the World Anti-Doping Agency (WADA) due to its potential for abuse and side effects.
Pharmacokinetics and Pharmacodynamics
When comparing SARMs and Tamoxifen, it is important to understand their pharmacokinetics and pharmacodynamics. SARMs are typically taken orally and have a longer half-life than traditional steroids, meaning they can be taken less frequently (Thevis et al. 2019). They also have a higher bioavailability, meaning a larger percentage of the drug is absorbed and available for use in the body.
Tamoxifen, on the other hand, is also taken orally but has a shorter half-life and lower bioavailability compared to SARMs (Jordan 2003). This means it needs to be taken more frequently and in higher doses to achieve the desired effects.
In terms of pharmacodynamics, SARMs and Tamoxifen have different mechanisms of action. SARMs selectively bind to androgen receptors, leading to an increase in muscle mass and strength, while Tamoxifen blocks estrogen receptors, leading to an increase in testosterone levels. However, both have been shown to have similar effects on muscle growth and performance in clinical trials (Kearbey et al. 2007; Velders et al. 2014).
Benefits and Risks
Both SARMs and Tamoxifen have potential benefits for athletes, but they also come with risks. SARMs have been shown to increase muscle mass and strength, improve physical function, and have a lower risk of side effects compared to traditional steroids (Thevis et al. 2019). However, they are still relatively new and have not been extensively studied in humans, so their long-term effects are not fully understood.
Tamoxifen, on the other hand, has been studied for decades and has a well-established safety profile. It has been shown to increase testosterone levels and improve muscle strength and endurance, making it an attractive option for athletes looking to enhance their performance (Velders et al. 2014). However, it also comes with a higher risk of side effects, including blood clots, stroke, and endometrial cancer (Jordan 2003).
Real-World Examples
The use of SARMs and Tamoxifen in sports is not uncommon, with many athletes turning to these substances to gain a competitive edge. In 2019, a professional cyclist was banned for four years after testing positive for Ostarine, a SARM, in a doping control (USADA 2019). In another case, a bodybuilder was banned for two years after testing positive for Tamoxifen (USADA 2018). These examples highlight the prevalence of these substances in the sports world and the potential consequences for athletes who use them.
Expert Opinion
While both SARMs and Tamoxifen have potential benefits for athletes, it is important to consider the risks and potential consequences of their use. As with any performance-enhancing substance, the decision to use SARMs or Tamoxifen should not be taken lightly and should be done under the guidance of a medical professional. It is also important for athletes to be aware of the potential for these substances to be banned by sports organizations and to adhere to anti-doping regulations.
References
Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., … & Steiner, M. S. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Journal of cachexia, sarcopenia and muscle, 2(3), 153-161.
Gao, W., Kim, J., Dalton, J. T., & Pharm, D. (2005). Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical research, 22(11), 1821-1830.
Jordan, V. C. (2003). Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2(3), 205-213.
Kearbey, J. D., Gao, W., Narayanan, R., Fisher, S. J